Alexion Pharmaceuticals PT Raised to $150.00 (ALXN)
Equities researchers at UBS AG hoisted their price target on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $130.00 to $150.00 in a research report issued on Monday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. UBS AG’s price objective would indicate a potential upside of 13.88% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of Alexion Pharmaceuticals from $138.00 to $161.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Goldman Sachs Group Inc. downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Finally, analysts at Piper Jaffray initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $172.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $128.50.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.75% during mid-day trading on Monday, hitting $129.42. 484,765 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $134.27. The stock’s 50-day moving average is $125. and its 200-day moving average is $113.5. The company has a market cap of $25.376 billion and a P/E ratio of 74.50.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.